SCHEMBL14770337

SCHEMBL14770337

Cc1nc2ccccn2c1C(=O)NCC1CCN(C(=O)OC(C)(C)C)CC1

nearest known ligand 0.62

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 7/20 0.62
PKM P14618 2/20 0.62
HSD17B10 Q99714 2/20 0.54
NPSR1 Q6W5P4 1/20 0.54
ALDH1A1 P00352 4/20 0.52
KMT2A Q03164 2/20 0.51
GAA P10253 1/20 0.51
POLB P06746 1/20 0.51
MAPT P10636 1/20 0.51
TDP1 Q9NUW8 1/20 0.51
HPGD P15428 1/20 0.50
LMNA P02545 1/20 0.49
HTT P42858 1/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
TSHR P16473 1/20 0.48
TP53 P04637 1/20 0.47
HTR4 Q13639 1/20 0.46
METTL3 Q86U44 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14761388 0.86 KDM4E (0.61) KDM4EPKMHSD17B10NPSR1ALDH1A1
SCHEMBL12295300 0.80 KDM4E (0.63) KDM4EPKMHSD17B10NPSR1ALDH1A1
SCHEMBL26131403 0.77 KDM4E (1.00) KDM4EPKMKMT2ATP53
SCHEMBL6984094 0.75 KDM4E (0.71) KDM4EPKMMAPTLMNATP53
SCHEMBL13947430 0.74 KDM4E (0.80) KDM4EPKMKMT2ALMNASMN1; SMN2
SCHEMBL10144835 0.74 KDM4E (0.76) KDM4EPKMKMT2A
SCHEMBL17796229 0.74 KDM4E (0.72) KDM4EPKMMAPTLMNATP53
SCHEMBL8206262 0.73 KDM4E (0.64) KDM4EPKMKMT2ATP53
SCHEMBL6979528 0.72 KDM4E (0.76) KDM4EPKMALDH1A1TP53
SCHEMBL15661860 0.72 KDM4E (0.80) KDM4EPKMNPSR1KMT2AMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2547678-B1 ANTI-INFECTIVE COMPOUNDS PASTEUR INSTITUT KOREA (KR) 2016-03-16 EP disclosed
US-9029389-B2 Anti-inflammation compounds INSTITUT PASTEUR KOREA (KR) 2015-05-12 US disclosed
US-9029389-B2 Anti-inflammation compounds INSTITUT PASTEUR KOREA (KR) 2015-05-12 US disclosed
US-8865734-B2 Anti-infective compounds INSTITUT PASTEUR KOREA (KR) 2014-10-21 US disclosed
US-8865734-B2 Anti-infective compounds INSTITUT PASTEUR KOREA (KR) 2014-10-21 US disclosed
US-20140155387-A1 Anti-Inflammation Compounds QURIENT, CO. LTD. (KR) 2014-06-05 US disclosed
US-20140155387-A1 Anti-Inflammation Compounds QURIENT, CO. LTD. (KR) 2014-06-05 US disclosed
US-20130065884-A1 Anti-Infective Compounds INSTITUT PASTEUR KOREA (KR) 2013-03-14 US disclosed
US-20130065884-A1 Anti-Infective Compounds INSTITUT PASTEUR KOREA (KR) 2013-03-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130065884-A1 Anti-Infective Compounds RABGGTB, ELANE, SERPINB1 KDM4E 4439/4885PKM 4244/4885HSD17B10 2718/4885
US-20140155387-A1 Anti-Inflammation Compounds NR0B1, NR0B2, NR5A2 KDM4E 2886/4885PKM 4718/4885HSD17B10 1085/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.